A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Trial Profile

A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Iron overload
  • Focus Adverse reactions
  • Acronyms E.C.L.I.P.S.E.; ECLIPSE
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 25 Jun 2017 Results of post hoc analysis of Eclipse trial presented at the 22nd Congress of the European Haematology Association
    • 06 Dec 2016 Results analysing safety of new film-coated tablet formulation of Deferasirox presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results reporting patient-reported outcomes, during the 24-week (wk) study period, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top